Description:
IC50 Value: N/A
AGI-5198, a novel R132H-IDH1 inhibitor, identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy. Isocitrate dehydrogenase 1 (IDH1) is one potential drug target, which is mutated in multiple human cancers [1].
in vitro: N/A
in vivo: N/A
Clinical trial: N/A